Placental expression of VEGF is increased in pregnancies with hydatidiform mole: Possible association with developing very early onset preeclampsia

Early Human Development

Volumn 89, Issue 8, 2013, Pages 583-588

  Zhao, Min ^a   Yin, Yongxiang ^a   Guo, Fang ^b   Wang, Jiajun ^a   Wang, Ke ^c   Chen, Qi ^a,d  

^a The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University   (China)

^b OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

^c JIANGSU INSTITUTE OF NUCLEAR MEDICINE   (China)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Endoglin; Hydatidiform mole; Preeclampsia; VEGF

Indexed keywords

ENDOGLIN; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; ONSET AGE; PLACENTA; PREECLAMPSIA; PREGNANCY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; ANTIGENS, CD; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDATIDIFORM MOLE; MIDDLE AGED; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, CELL SURFACE; RISK FACTORS; TRANSCRIPTION, GENETIC; UTERINE NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879845051     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2013.02.008     Document Type: Article

References (35)

1. Berkowitz R.S., Goldstein D.P. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009, 112:654-662.
2. Jacobs P.A., Hunt P.A., Matsuura J.S., Wilson C.C., Szulman A.E. Complete and partial hydatidiform mole in Hawaii: cytogenetics, morphology and epidemiology. Br J Obstet Gynaecol 1982, 89:258-266.
3. Moore L.E. Recurrent risk of adverse pregnancy outcome. Obstet Gynecol Clin North Am 2008, 35:459-471. [ix].
4. Seckl M.J., Sebire N.J., Berkowitz R.S. Gestational trophoblastic disease. Lancet 2010, 376:717-729.
5. Cunningham F.G., Leveno K.L., Bloom S.L., Hauth J.C., Gilstrap L.C., Westrom K.D. Gestational trophoblastic diseases (chapter 11) in Williams obstetrics 2010, 23rd ed.
6. Jauniaux E. Partial moles: from postnatal to prenatal diagnosis. Placenta 1999, 20:379-388.
7. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
8. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658.
9. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., Wang W. Evaluation of placenta growth factor and soluble fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006, 195:255-259.
10. Gale N.W., Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999, 13:1055-1066.
11. Clark D.E., Smith S.K., He Y., Day K.A., Licence D.R., Corps A.N., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998, 59:1540-1548.
12. Koga K., Osuga Y., Tajima T., Hirota Y., Igarashi T., Fujii T., et al. Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2010, 94:305-308.
13. Stepan H., Faber R. Cytomegalovirus-induced mirror syndrome associated with elevated levels of angiogenic factors. Obstet Gynecol 2007, 109:1205-1206. [author reply 1206].
14. Soto-Wright V., Bernstein M., Goldstein D.P., Berkowitz R.S. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 1995, 86:775-779.
15. Espinoza J., Uckele J.E., Starr R.A., Lorenz R.P., Bronsteen R.A., Berry S.M. Insights into angiogenic imbalances during pregnancy. Obstet Gynecol 2009, 114:437-440.
16. Kanter D., Lindheimer M., Wang E., Borromeo R., Bousfield E., Karumanchi S., et al. Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol 2010, 202:184.
17. Chen Q., Stone P., Ching L., Chamley L. A role for interleukin 6 in spreading endothelial cell activation after phagocytosis of necrotic trophoblastic material: implications for the pathogenesis of preeclampsia. J Pathol 2009, 217:122-130.
18. Chen L., Liu B., Zhao H., Stone P., Chen Q., Chamley L. IL-6, TNF [alpha] and TGF [beta] promote nonapoptotic trophoblast deportation and subsequently causes endothelial cell activation. Placenta 2010, 31:75-80.
19. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89:2637-2645.
20. Bonanomi A., Kojic D., Giger B., Rickenbach Z., Jean-Richard-Dit-Bressel L., Berger C., et al. Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing. J Immunol Methods 2003, 283:27-43.
21. Berkowitz R.S., Goldstein D.P. Chorionic tumors. N Engl J Med 1996, 335:1740-1748.
22. Hsieh F.J., Wu C.C., Lee C.N., Chen T.M., Chen C.A., Chen F.C., et al. Vascular patterns of gestational trophoblastic tumors by color Doppler ultrasound. Cancer 1994, 74:2361-2365.
23. Prasannan-Nair C., Reynolds S.F., Budden G. Partial molar pregnancy with severe pre-eclampsia at 19weeks' gestation. J Obstet Gynaecol 2006, 26:817.
24. Lam C., Lim K.H., Karumanchi S.A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005, 46:1077-1085.
25. Nomura S., Okamoto T., Matsuo K., Iwase K., Nakanishi T., Suzuki H., et al. Serum and tissue vascular endothelial growth factor levels in hydatidiform mole. Life Sci 1998, 63:1793-1805.
26. Bolat F., Haberal N., Tunali N., Aslan E., Bal N., Tuncer I. Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor 1 alpha (HIF-1alpha), and transforming growth factors beta1 (TGFbeta1) and beta3 (TGFbeta3) in gestational trophoblastic disease. Pathol Res Pract 2010, 206:19-23.
27. Ahmed A., Li X.F., Dunk C., Whittle M.J., Rushton D.I., Rollason T. Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors 1995, 12:235-243.
28. Jackson M.R., Carney E.W., Lye S.J., Ritchie J.W. Localization of two angiogenic growth factors (PDECGF and VEGF) in human placentae throughout gestation. Placenta 1994, 15:341-353.
29. Nagymanyoki Z., Growdon W.B., Sarno J., Callahan M.J., Parast M.M., Fulop V., et al. Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med 2008, 53:589-594.
30. Pathology of the human placenta 2006, Springer-Verlag, New York. 5th ed. K.K.P. Benirschke, R. Baergen (Eds.).
31. Reynolds S.R. Hydatidiform mole: a vascular congenital anomaly. Obstet Gynecol 1976, 47:244-250.
32. Qiao S., Nagasaka T., Nakashima N. Numerous vessels detected by CD34 in the villous stroma of complete hydatidiform moles. Int J Gynecol Pathol 1997, 16:233-238.
33. Reisinger K., Baal N., McKinnon T., Munstedt K., Zygmunt M. The gonadotropins: tissue-specific angiogenic factors?. Mol Cell Endocrinol 2007, 269:65-80.
34. Baumann M.U., Bersinger N.A., Mohaupt M.G., Raio L., Gerber S., Surbek D.V. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008, 199. 266 e1-e6.
35. Chaiworapongsa T., Espinoza J., Gotsch F., Kim Y.M., Kim G.J., Goncalves L.F., et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008, 21:25-40.